natgillin/translations-raw huggingface dataset:
For patients with chronic kidney failure or receiving chemotherapy, haemoglobin levels should remain within the recommended range (between 10 and 12 grams per decilitre in adults and between 9.5 and 11 g/dl in children).
Za bolesnike s kroničnim zatajenjem bubrega ili bolesnika koji primaju kemoterapiju, koncentracije hemoglobina trebaju ostati unutar preporučenog raspona (između 10 i 12 grama po decilitru u odraslih osoba i između 9,5 i 11g/dl u djece).
For patients with CLL the recommended dose of Gazyvaro in combination with chlorambucil is shown in Table 3.
Preporučena doza lijeka Gazyvaro u kombinaciji s klorambucilom za bolesnike s KLL-om prikazana je u Tablici 3.
For patients with concomitant moderate to severe plaque psoriasis or who are anti-TNFα inadequate responders (IR), the recommended dose is 300 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4.
Za bolesnike s istodobnom umjerenom do teškom plak psorijazom ili one koji imaju neodgovarajući odgovor (NO) na anti-TNFα, preporučena doza je 300 mg supkutanom injekcijom s početnom dozom u 0., 1., 2. i 3. tjednu, nakon čega slijedi mjesečna doza održavanja počevši od 4. tjedna.
For patients with COPD cessation of therapy may also be associated with symptomatic decompensation and should be supervised by a physician.
I u bolesnika s KOPB-om prestanak terapije može biti povezan sa simptomatskom dekompenzacijom i treba se provesti pod nadzorom liječnika.
For patients with COPD experiencing exacerbations, treatment with systemic corticosteroids is typically indicated, therefore patients should be instructed to seek medical attention if symptoms deteriorate with Aerivio Spiromax.
Bolesnicima s KOPB-om koji imaju egzacerbacije obično je indicirano liječenje sistemskim kortikosteroidima; stoga bolesnicima treba savjetovati da potraže liječničku pomoć ako im se simptomi pogoršavaju uz Aerivio Spiromax.
For patients with COPD experiencing exacerbations, treatment with systemic corticosteroids is typically indicated, therefore patients should be instructed to seek medical attention if symptoms deteriorate with Aerivio Spiromax.
Bolesnicima s KOPB-om koji imaju egzacerbacije obično je indicirano liječenje sistemskim kortikosteroidima; stoga bolesnicima treba savjetovati da potraže liječničku pomoć ako im se simptomi pogoršavaju uz Airexar Spiromax.
For patients with CrCl < 60 mL/min, alternative antibacterials should be considered.
U pacijenata s CrCl < 60 ml/min treba razmotriti alternativne antibakterijske lijekove.
For patients with creatinine clearance 10-19 ml/min: Administration of 33 mg (1 scoop) tenofovir disoproxil (as fumarate) 33 mg/g granules once daily is recommended.
Za pacijente s klirensom kreatinina 10-19 ml/min: preporučuje se primjena 33 mg (1 mjerna žličica) tenofovirdizoproksila (u obliku tenofovirdizoproksilfumarata) 33 mg/g granula jedanput na dan.
For patients with creatinine clearance 20-29 ml/min: Administration of 65 mg (2 scoops) tenofovir disoproxil (as fumarate) 33 mg/g granules once daily is recommended.
Za pacijente s klirensom kreatinina 20-29 ml/min: preporučuje se primjena 65 mg (2 mjerne žličice) tenofovirdizoproksila (u obliku tenofovirdizoproksilfumarata) 33 mg/g granula jedanput na dan.
For patients with creatinine clearance <30 mL/minute, additional considerations are necessary because elimination of enoxaparin is more prolonged.
Za bolesnike s klirensom kreatinina <30 ml/minuti potreban je dodatni oprez jer je kod njih vrijeme eliminacije enoksaparina duže.
For patients with diabetes mellitus, the dose of insulin may need adjustment after NutropinAq therapy is initiated.
Za bolesnike s dijabetesom melitusom dozu inzulina će možda biti potrebno prilagoditi nakon početka liječenja lijekom NutropinAq.
For patients with diabetes mellitus, the insulin dose may require adjustment after NutropinAq therapy is instituted.
Kod bolesnika sa šećernom bolesti dozu inzulina možda će trebati prilagoditi nakon početka liječenja lijekom NutropinAq.
For patients with EBC, cardiac assessments, as performed at baseline, should be repeated every 3 months during treatment and every 6 months following discontinuation of treatment until 24 months from the last administration of Herceptin.
U bolesnika s ranim rakom dojke, kardiološki pregled istovjetan onom obavljenom u sklopu početne procjene, potrebno je ponavljati svaka 3 mjeseca tijekom liječenja te svakih 6 mjeseci nakon završetka liječenja do 24 mjeseca od posljednje primjene lijeka Herceptin.
For patients with ECOG 2 performance status, assessment of benefit-risk is recommended prior to initiation of Vectibix in combination with chemotherapy for treatment of mCRC.
Kod bolesnika s izvedbenim statusom ECOG 2 preporuča se procjena koristi i rizika prije započinjanja liječenja mKRK-a lijekom Vectibix u kombinaciji s kemoterapijom.
For patients with elevated AST or ALT in the range of > 5-≤ 8 x ULN or total bilirubin in the range of > 3-≤ 5 x ULN that is suspected to be related to ipilimumab, the scheduled dose of ipilimumab should be withheld, and LFTs must be monitored until resolution.
U bolesnika s povišenim vrijednostima AST ili ALT u rasponu od > 5-≤ 8 x GGN ili ukupnog bilirubina u rasponu od > 3-≤ 5 x GGN za koje se vjeruje da su povezane s ipilimumabom, treba odgoditi primjenu planirane dozu ipilimumaba i pratiti LFT do potpunog povlačenja.
For patients with ESRD, Sebivo should be administered after haemodialysis (see section 5.2).
U bolesnika s ESRD-om Sebivo treba primjenjivati nakon hemodijalize (vidjeti dio 5.2).
For patients with evidence of CMV viraemia and clinical signs of CMV infection, consideration should be given to interrupting idelalisib until the infection has resolved.
Za pacijente s dokazanom CMV viremijom i kliničkim znakovima infekcije CMV-om potrebno je razmotriti prekidanje liječenja idelalisibom sve dok se infekcija ne povuče.
For patients with FL, the recommended dose of Gazyvaro in combination with bendamustine is shown in Table 4.
Preporučena doza lijeka Gazyvaro u kombinaciji s bendamustinom za bolesnike s FL-om prikazana je u Tablici 4.
For patients with kidney failure or receiving chemotherapy, haemoglobin levels should remain within the recommended range (between 10 and 12 grams per decilitre in adults and between 9.5 and 11 g/dl in children).
Za bolesnike s kroničnim zatajenjem bubrega ili bolesnika koji primaju kemoterapiju, koncentracije hemoglobina trebaju ostati unutar preporučenog raspona (između 10 i 12 grama po decilitru u odraslih osoba i između 9,5 i 11g/dl u djece).
For patients with lung cancer, doctors should test the tumours to check if the cancer cells produce the PD-L1 protein before starting treatment.
Za bolesnike s rakom pluća liječnici prije započinjanja terapije trebaju ispitati tumore kako bi provjerili proizvode li stanice raka bjelančevinu PD-L1.
For patients with LVDr substitutions at baseline, the percentage of patients with HBV DNA
Među bolesnicima s LVDr supstitucijama na početku ispitivanja, postotak bolesnika s HBV DNK
For patients with mantle cell lymphoma, it is recommended that coadministration of CYP3A4/5 inducers should be avoided due to the higher dose of temsirolimus (see section 4.5).
U bolesnika s limfomom plaštenih stanica preporučuje se izbjegavati istodobnu primjenu induktora CYP3A4/5 zato što primaju više doze temsirolimusa (vidjeti dio 4.5).
For patients with mantle cell lymphoma, the average time before the disease got worse was 37.6 weeks in those treated with Revlimid, compared with 22.7 weeks in those given other treatments.
U bolesnika s limfomom plaštenih stanica, u onih liječenih lijekom Revlimid prosječno vrijeme do pogoršanja bolesti iznosilo je 37,6 tjedana, dok je u bolesnika koji su primali druge terapije to vrijeme iznosilo 22,7 tjedana.
For patients with mild or moderate hepatic impairment, no dose adjustment is required.
U bolesnika s blagim do umjerenim oštećenjem jetre, prilagodba doze nije potrebna.
For patients with mild renal impairment (CLcr ≥50 and <80 mL/min) no dosage adjustment is necessary.
Za bolesnike s blagim oštećenjem bubrega (klirens kreatinina ≥50 i <80 ml/min) nije potrebna prilagodba doze.
For patients with mild renal impairment (CLcr ≥50 and <80 mL/min) no dose adjustment is necessary.
Za bolesnike s blagim oštećenjem bubrega (klirens kreatinina ≥ 50 i < 80 ml/min) nije potrebna prilagodba doze.
For patients with mild renal impairment (CLcr ≥50 and <80 mL/min) no doseadjustment is necessary.
Za bolesnike s blagim oštećenjem bubrega (klirens kreatinina ≥ 50 i < 80 ml/min) nije potrebna prilagodba doze.
For patients with mild renal impairment (creatinine clearance > 50 to ≤ 80 mL/min), no dose adjustment of alogliptin is necessary (see section 5.2).
U bolesnika s blagim oštećenjem bubrega (klirens kreatinina >50 do ≤ 80 ml/min) nije potrebna prilagodba doze alogliptina (vidjeti dio 5.2).
For patients with mild renal impairment (creatinine clearance > 50 to ≤ 80 mL/min), no dose adjustment of Incresync is necessary (see section 5.2).
Za bolesnike s blagim oštećenjem bubrega (klirens kreatinina >50 do ≤ 80 ml/min) nije potrebna prilagodba doze Incresynca (vidjeti dio 5.2).
For patients with mild renal impairment (creatinine clearance [CrCl]  50 ml/min), no dose adjustment is required.
U bolesnika s blagim oštećenjem funkcije bubrega (klirens kreatinina [CrCl] ≥ 50 ml/min) nije potrebna prilagodba doze.
For patients with mild renal impairment (creatinine clearance [CrCl] 50 ml/min), no dose adjustment is required.
U bolesnika s blagim oštećenjem funkcije bubrega (klirens kreatinina [CrCl] ≥ 50 ml/min) nije potrebna prilagodba doze.
For patients with mild renal impairment (creatinine clearance ≥ 50 ml/min to < 80 ml/min), dose should be adjusted and the patient stabilised using 1-monthly paliperidone palmitate injectable, then transitioned to TREVICTA.
Kod bolesnika s blagim oštećenjem bubrega (klirens kreatinina ≥ 50 do < 80 ml/min) potrebno je prilagoditi dozu, te bolesnika stabilizirati na paliperidonpalmitatu u obliku 1-mjesečne injekcije i tada prijeći na lijek TREVICTA.
For patients with mild renal impairment (creatinine clearance ≥ 50 to < 80 ml/min), dose should be adjusted and the patient stabilised using 1-monthly paliperidone palmitate injectable, and then transitioned to TREVICTA.
U bolesnika s blagim oštećenjem bubrežne funkcije (klirens kreatinina ≥ 50 do < 80 ml/min) potrebno je prilagoditi dozu i bolesnike stabilizirati uz uporabu paliperidonpalmitata u obliku 1-mjesečne injekcije, te nakon toga prijeći na lijek TREVICTA.
For patients with mild renal impairment (creatinine clearance ≥ 50 to < 80 ml/min), the recommended initial dose is 3 mg once daily.
Kod bolesnika s blagim oštećenjem bubrega (klirens kreatinina ≥ 50 do < 80 ml/min) preporučuje se početna doza od 3 mg jedanput dnevno.
For patients with mild renal impairment (creatinine clearance ≥ 60 mL/min), no dose adjustment of Vipdomet is necessary (see section 5.2).
Za bolesnike s blagim oštećenjem bubrega (klirens kreatinina ≥60 ml/min) nije potrebna prilagodba doze Vipdometa (vidjeti dio 5.2).
For patients with missing baseline data, latest screening/unscheduled data was carried forward to baseline. b Complete resolution of constitutional symptoms (fever, night sweats, fatigue, weight loss) defined as the presence of any symptoms at baseline, followed by no symptoms present. c Lymphadenopathy measured by sum of the products of greatest diameters (SPD) as assessed by physical examination.
Za bolesnike u kojih su nedostajale početne vrijednosti, kao početne vrijednosti uzeli su se podaci od posljednjeg probira/neplanirane posjete. b Potpuni oporavak od općih simptoma (vrućice, noćnog znojenja, umora, gubitka težine) definiran kao prisustvo bilo kojih simptoma na početku, koji su kasnije nestali. c Limfadenopatija mjerena kao zbroj tvorbi najvećeg promjera procijenjenih tijekom liječničkog pregleda.
For patients with moderate hepatic impairment (Child-Pugh Class B), a dose reduction to two tablets in the morning and one tablet in the evening (lumacaftor 600 mg/ivacaftor 375 mg total daily dose) is recommended (see section 5.2).
Bolesnicima s umjerenim oštećenjem funkcije jetre (Child-Pugh stadij B) preporučuje se smanjenje doze na dvije tablete ujutro i jednu tabletu navečer (ukupna dnevna doza je 600 mg lumakaftora/375 mg ivakaftora) (vidjeti dio 5.2).
For patients with moderate hepatic impairment (Child-Pugh Class B), a reduced dose of 150 mg once daily is recommended.
U bolesnika s umjerenim oštećenjem funkcije jetre (Child-Pugh stadij B) preporučuje se snižena doza od 150 mg jedanput na dan.
For patients with moderate hepatic impairment (Child-Pugh Class B), a reduced dose of 50 mg once daily is recommended in patients aged 2 years and older with body weight less than 14 kg and 75 mg once daily for those with body weight 14 kg to less than 25 kg.
U bolesnika s umjerenim oštećenjem funkcije jetre (Child-Pugh stadij B) u dobi od 2 i više godina i tjelesne težine manje od 14 kg preporučuje se snižena doza od 50 mg jedanput na dan, a 75 mg jedanput na dan u onih tjelesne težine između 14 kg i manje od 25 kg.
For patients with moderate or severe hepatic impairment the maximum dose is 92/22 micrograms (see section 4.4).
Najveća doza za bolesnike s umjerenim ili teškim oštećenjem jetrene funkcije je 92/22 mikrograma (vidjeti dio 4.4).
For patients with moderate or severe renal impairment where the decision has been taken for 15 mg once daily from Day 22 onwards, other presentations only containing 15 mg film-coated tablets are available (see dosing instructions in section Special populations below).
Za bolesnike s umjerenim ili teškim oštećenjem funkcije bubrega za koje je odlučeno da uzimaju dozu od 15 mg jedanput na dan od 22. dana nadalje, dostupna su druga pakiranja koja sadrže samo 15 mg filmom obložene tablete (vidjeti upute za doziranje u dijelu Posebne populacije ispod).
For patients with moderate renal impairment (CLcr ≥30 and <50 mL/min) a dosage adjustment to one 50 mg film-coated tablet every second day is recommended (see section 5.2).
Za bolesnike s umjerenim oštećenjem bubrega (klirens kreatinina ≥30 i <50 ml/min) preporučena je prilagodba doze na jednu 50 mg filmom obloženu tabletu svaki drugi dan (vidjeti dio 5.2).
For patients with moderate renal impairment (CrCL 30-50 mL/min) the recommended dose of Pradaxa is also 300 mg taken as one 150 mg capsule twice daily.
Za bolesnike s umjerenim oštećenjem bubrega (CrCL 30 - 50 mL/min) preporučena doza Pradaxe je također 300 mg u obliku jedne kapsule od 150 mg dvaput dnevno.
For patients with moderate renal impairment (CrCl  30 to < 50 mL/min), the dose of Januvia is 50 mg once daily.
U bolesnika s umjerenim oštećenjem funkcije bubrega (CrCl ≥ 30 do < 50 ml/min) doza lijeka Januvia je 50 mg jedanput na dan.
For patients with moderate renal impairment (CrCl  30 to < 50 mL/min), the dose of Ristaben is 50 mg once daily.
U bolesnika s umjerenim oštećenjem funkcije bubrega (CrCl ≥ 30 do < 50 ml/min) doza lijeka Ristaben je 50 mg jedanput na dan.
For patients with moderate renal impairment (CrCl  30 to < 50 mL/min), the dose of TESAVEL is 50 mg once daily.
U bolesnika s umjerenim oštećenjem funkcije bubrega (CrCl ≥ 30 do < 50 ml/min) doza lijeka TESAVEL je 50 mg jedanput na dan.
For patients with moderate renal impairment (CrCl  30 to < 50 mL/min), the dose of Xelevia is 50 mg once daily.
U bolesnika s umjerenim oštećenjem funkcije bubrega (CrCl ≥ 30 do < 50 ml/min) doza lijeka Xelevia je 50 mg jedanput na dan.
For patients with moderate renal impairment (creatinine clearance 31 to 50 ml/min) the recommended dose of Lynparza is 300 mg twice daily (equivalent to a total daily dose of 600 mg) (see section 5.2).
Kod bolesnica s umjerenim oštećenjem bubrežne funkcije (klirens kreatinina od 31 do 50 ml/min) preporučena doza lijeka Lynparza je 300 mg dva puta na dan (ekvivalent ukupnoj dnevnoj dozi od 600 mg) (vidjeti dio 5.2).
For patients with moderate renal impairment (creatinine clearance ≥ 30 to ≤ 50 mL/min), one-half of the recommended dose of alogliptin should be administered (12.5 mg once daily; see section 5.2).
U bolesnika s umjerenim oštećenjem bubrega (klirens kreatinina ≥ 30 do ≤ 50 ml/min) potrebno je primijeniti jednu polovicu preporučene doze alogliptina (12,5 mg jedanput na dan; vidjeti dio 5.2).
For patients with moderate renal impairment (creatinine clearance ≥ 30 to ≤ 50 mL/min), one-half of the recommended dose of alogliptin should be administered.
Za bolesnike s umjerenim oštećenjem bubrega (klirens kreatinina ≥ 30 do ≤ 50 ml/min) potrebno je primijeniti polovicu preporučene doze alogliptina.
For patients with moderate renal impairment who experience adverse reactions that are not tolerable, dosing may be reduced to 1 mg once daily.
U bolesnika s umjerenim oštećenjem bubrežne funkcije u kojih se jave nuspojave koje se ne mogu podnijeti, doza se može smanjiti na 1 mg jedanput na dan.
For patients with moderate to severe renal impairment (creatinine clearance  10 to < 50 ml/min), the recommended initial dose of INVEGA is 1.5 mg every day, which may be increased to 3 mg once daily after clinical reassessment.
Kod bolesnika s umjerenim do teškim oštećenjem bubrega (klirens kreatinina  10 do < 50 ml/min) preporučuje se inicijalna doza od 1,5 mg svaki dan, koja se može povećati na 3 mg jednom dnevno nakon ponovne kliničke procjene.
For patients with multiple symmetrical painful or swollen joints (e.g., hands, wrists and feet), Benepali can slow down the structural damage to those joints caused by the disease.
Benepali može usporiti napredovanje strukturnog oštećenja zglobova koje uzrokuje bolest kod bolesnika s više simetrično bolnih ili otečenih zglobova (npr. šake, zapešća i stopala).
For patients with multiple symmetrical painful or swollen joints (e.g., hands, wrists and feet), Benepali can slow down the structural damage to those joints caused by the disease.
Benepali može usporiti napredovanje strukturnog oštećenja zglobova koje uzrokuje bolest kod bolesnika s više simetrično bolnih ili otečenih zglobova (npr. šake,zapešća i stopala).
For patients with multiple symmetrical painful or swollen joints (e.g., hands, wrists and feet), Enbrel can slow down the structural damage to those joints caused by the disease.
Enbrel može usporiti napredovanje strukturnog oštećenja zglobova koje uzrokuje bolest kod bolesnika s više simetrično bolnih ili otečenih zglobova (npr. šake, zapešća i stopala).
For patients with normal baseline serum creatinine (< 1.4 mg/dl or < 124 µmol/l), an increase of 0.5 mg/dl or 44 µmol/l;
povišenje vrijednosti kreatinina za 0,5 mg/dl ili 44 μmol/l u bolesnika s normalnom početnom vrijednošću kreatinina u serumu (< 1,4 mg/dl ili < 124 μmol/l)
For patients with normal baseline serum creatinine (< 1.4 mg/dl or < 124 µmol/l), an increase of 0.5 mg/dl or 44 µmol/l;
povišenje vrijednosti kreatinina za 0,5 mg/dl ili 44 μmol/l, u bolesnika s normalnom početnom vrijednošću kreatinina u serumu (< 1,4 mg/dl ili < 124 μmol/l),
For patients with NSCLC other than predominantly squamous cell histology (n = 430, independently reviewed population) median PFS was 4.4 months for the pemetrexed arm and 1.8 months for the placebo arm, hazard ratio = 0.47 (95% CI = 0.37-0.60, p = 0.00001).
U bolesnika s NSCLC-om kod kojeg histološki ne prevladavaju pločaste stanice (n=430, neovisno procijenjena populacija), medijan PFS-a bio je 4,4 mjeseci u skupini koja je primala pemetreksed te 1,8 mjeseci u skupini koja je primala placebo, omjer hazarda= 0,47 (95% CI = 0,37-0,60, p = 0,00001).
For patients with NSCLC other than predominantly squamous cell histology (N = 430, independently reviewed population) median PFS was 4.4 months for the pemetrexed arm and 1.8 months for the placebo arm, hazard ratio = 0.47 (95% CI = 0.37-0.60, p = 0.00001).
U bolesnika s NSCLC-om kod kojeg histološki ne prevladavaju skvamozne stanice (N =430, neovisno procijenjena populacija), medijan PFS-a bio je 4,4 mjeseci u skupini koja je primala pemetreksed te 1,8 mjeseci u skupini koja je primala placebo, omjer hazarda = 0,47 (95% CI = 0,37-0,60, p = 0,00001).
For patients with NVAF treated for prevention of stroke and SEE and for DVT/PE patients, concomitantly receiving dabigatran etexilate and verapamil, the dose of Pradaxa should be reduced to 220 mg taken as one 110 mg capsule twice daily (see section 4.2).
Za bolesnike s NVAF-om koji se liječe radi prevencije moždanog udara i SE-a, te DVT/PE-a, a koji istodobno primjenjuju dabigataneteksilat i verapamil, doza Pradaxe se snižava na 220 mg u obliku jedne kapsule od 110 mg dvaput dnevno (vidjeti dio 4.2).
For patients with operable node-negative breast cancer, adjuvant treatment should be resticted to patients eligible to receive chemotherapy according to internationally established crieteria from primary therapy of early breast cancer (see section 5.1).
U bolesnika s operabilnim karcinomom dojke i negativnim limfnim čvorovima, adjuvantno liječenje treba ograničiti samo na bolesnike koji su prikladni za primanje kemoterapije prema međunarodno utvrđenim kriterijima za primarnu terapiju ranog karcinoma dojke (vidjeti dio 5.1).
For patients with other heart problems, Uptravi must only be used under close medical supervision.
U slučaju bolesnika s drugim problemima sa srcem, lijek Uptravi mora se primjenjivati samo pod strogim medicinskim nadzorom.
For patients with partial DPD deficiency (such as those with heterozygous mutations in the DPYD gene) and where the benefits of Xeloda are considered to outweigh the risks (taking into account the suitability of an alternative non-fluoropyrimidine chemotherapeutic regimen), these patients must be treated with extreme caution and frequent monitoring with dose adjusment according to toxicity.
U bolesnika s djelomičnim deficitom DPD-a (poput onih s heterozigotnim mutacijama u genu DPYD) i za koje se smatra da koristi liječenja lijekom Xeloda nadmašuju rizike (uzimajući u obzir prikladnost nekog drugog kemoterapijskog protokola koji ne uključuje fluoropirimidin), liječenje treba provoditi uz izniman oprez i sa čestim praćenjem uz prilagodbu doze sukladno toksičnosti.
For patients with Peyronie’s disease, Xiapex is given for up to 4 treatment cycles each lasting about 6 weeks.
U slučaju bolesnika s Peyronijevom bolešću, Xiapex se primjenjuje do maksimalno 4 terapijska ciklusa, pri čemu svaki ciklus traje otprilike 6 tjedana.
For patients with possible depletion of intravascular volume or salt depletion (e.g. patients with vomiting, diarrhoea or taking high doses of diuretics), Ipreziv should be initiated under close medical supervision and consideration can be given to 20 mg as a starting dose (see section 4.4).
Bolesnicima u kojih može biti smanjen intravaskularni volumen ili im može nedostajati elektrolita (npr. bolesnici koji povraćaju, imaju proljev ili uzimaju visoke doze diuretika), Ipreziv treba početi primjenjivati uz strogi medicinski nadzor, a može se razmotriti i primjena 20 mg kao početne doze (vidjeti dio 4.4).
For patients with previously treated baseline brain metastases, the median intracranial time to progression (IC-TTP) was 15.7 months in the crizotinib arm (N=39) and 12.5 months in the chemotherapy arm (N=40) (HR=0.45 [95% CI: 0.19, 1.07]; 1-sided p-value=0.0315).
Za bolesnike s prethodno liječenim metastazama na mozgu na početku ispitivanja, medijan intrakranijalnog vremena do progresije bolesti (IC-TTP) bio je 15,7 mjeseci u skupini krizotiniba (N=39) i 12,5 mjeseci u kemoterapijskoj skupini (N=40) (HR=0,45 [95% CI: 0,19; 1,07]; 1-strana p- vrijednost=0,0315).
For patients with prior failure on therapy with nonpegylated interferon or pegylated interferon and negative at week 12, the sustained response rates were 59 % and 50 %, respectively.
Trajan virološki odgovor ostvarilo je 59% bolesnika prethodno neuspješno liječenih nepegiliranim interferonom te 50% bolesnika prethodno neuspješno liječenih pegiliranim interferonom koji su imali negativan nalaz u